Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults
Authors:
- Gaëlle PédronoGPGaëlle Pédrono
- Jean-Michel MolinaJMJean-Michel Molina
- Cécile GoujardCGCécile Goujard
- Pierre-Marie GirardPGPierre-Marie Girard
- Nathalie SarrazinNSNathalie Sarrazin
- Christine KatlamaCKChristine Katlama
- Patrick YéniPYPatrick Yéni
- Pascale MorineauPMPascale Morineau
- Jean-François DelfraissyJDJean-François Delfraissy
- Geneviève ChêneGCGeneviève Chêne
- Yves LévyYLYves Lévy
- 30 November 2007
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 21 (18) , 2425-2434
Abstract
To evaluate whether a strategy combining a prime with a 7-valent conjugate pneumococcal vaccine (PCV) followed by a boost with the 23-valent polysaccharide vaccine (PPV) would improve immunogenicity against Streptococcus pneumoniae polysaccharides in HIV-infected patients. Randomized controlled phase II trial. Two-hundred and twelve patients with CD4 cell counts of 200–500 cells/μl and HIV RNA< 4 log10 copies/ml, regardless of antiretroviral treatment, were randomized to receive either PCV at week 0 and PPV at week 4 (n = 106) or PPV alone at week 4 (n = 106). The proportion of responders to 0, 1–2, 3–4, 5–7 serotypes shared by the two vaccines was evaluated at week 8 and compared using a proportional odds model allowing for adjustment for CD4 cell count, HIV RNA and antiretroviral treatment. At week 8, the profile of response was better in the prime-boost group compared to the PPV group, as determined by the frequency of patients who reached both a twofold increase of serotype-specific IgG levels and IgG level ≥ 1 μg/ml [proportional odds ratio (OR), 2.09; 95% confidence interval (CI), 1.25–3.51; P = 0.005]. No differences in responders were found 4 weeks after PCV or PPV alone, suggesting that PCV primed for response to PPV. Early differences between groups remained significant at week 24 (proportional OR, 2.14; 95% CI, 1.30–3.54; P = 0.003). In a setting of practical care, a PCV prime-PPV boost strategy enhances the frequency, breadth and magnitude of antibody responses against SPP in HIV-infected adults.Keywords
This publication has 58 references indexed in Scilit:
- Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990–2003AIDS, 2006
- Declining Incidence of InvasiveStreptococcus pneumoniaeInfections among Persons with AIDS in an Era of Highly Active Antiretroviral Therapy, 1995–2000The Journal of Infectious Diseases, 2005
- Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trialThe Lancet, 2005
- A Case‐Control Study to Investigate Serological Correlates of Clinical Failure of 23‐Valent Pneumococcal Polysaccharide Vaccine in HIV‐1–Infected Ugandan AdultsThe Journal of Infectious Diseases, 2004
- Pneumonia in HIV‐infected patients in the HAART era: Incidence, risk, and impact of the pneumococcal vaccinationJournal of Medical Virology, 2004
- A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV InfectionNew England Journal of Medicine, 2003
- Enzyme-Linked Immunosorbent Assay for Quantitation of Human Antibodies to Pneumococcal PolysaccharidesClinical and Vaccine Immunology, 2003
- Recurrent Invasive Pneumococcal Disease in Individuals with Human Immunodeficiency Virus InfectionThe Journal of Infectious Diseases, 2002
- Pneumococcal Conjugate Vaccine Primes for Polysaccharide‐Inducible IgG2 Antibody Response in Children with Recurrent Otitis Media AcutaThe Journal of Infectious Diseases, 1999
- Zidovudine Improves Response to Pneumococcal Vaccine among Persons with AIDS and AIDS-Related ComplexThe Journal of Infectious Diseases, 1991